Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Lasting Decreases in BP Obtained with Telmisartan + Amlodipine
July 13, 2009
- Concrete Reasons for Lack of Enthusiasm about Use of Generics to Be Determined
July 13, 2009
- Alogliptin Approval to Be Delayed at Least 2 Years: Takeda
July 6, 2009
- REGULATORY NEWS IN BRIEF
July 6, 2009
- Sandoz's Growth Hormone Approved as Japan's First Biosimilar
July 6, 2009
- JSGM Proposes Free Pricing System for Generics
July 6, 2009
- Korosho Asks MEXT to Cooperate to Increase Use of Generics by National Univ. Hospitals
July 6, 2009
- J&J to Launch Cor-Tyzine for Nasal Allergy
July 6, 2009
- Kyowa Kirin Initiates PII Trial for KW-0761 in Japan
July 6, 2009
- R&D NEWS IN BRIEF
July 6, 2009
- Korosho's Council Recommends Early Development of Plerixafor
July 6, 2009
- NEW PRODUCTS
July 6, 2009
- JSA Proposes Outline of Law on Measures against Stroke
July 6, 2009
- ExAblate 2000 Recommended for Approval for Treatment of Uterine Myoma
July 6, 2009
- GSK Makes Full Entry into Oncology Market with Tykerb
July 6, 2009
- ArBlast's Cultured Corneal Epithelial Cell Sheet Passes CDFS Committee
July 6, 2009
- Otsuka: Mainstay Products Drive Sales up to ¥440.4 Bil.
July 6, 2009
- 4 Med Materials Recommended for Health Insurance Coverage
July 6, 2009
- Bayer Moves Oncology Business Unit to Tokyo
July 6, 2009
- IP Injection of Paclitaxel Approved
July 6, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…